T L Burgess

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
    T L Burgess
    Department of Mammalian Cell Molecular Biology, Amgen Inc, Thousand Oaks, California 91320 1789, USA
    J Cell Biol 145:527-38. 1999
  2. ncbi Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
    Teresa Burgess
    Department of Oncology Research, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 1799, USA
    Cancer Res 66:1721-9. 2006
  3. ncbi Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor
    Teresa L Burgess
    Amgen Inc, Thousand Oaks, California 91320 1799, USA
    Mol Cancer Ther 9:400-9. 2010
  4. ncbi Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors
    J Faust
    Department of Pathology, Amgen Inc, Thousand Oaks, California 91320, USA
    J Cell Biochem 72:67-80. 1999
  5. ncbi Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
    D L Lacey
    Departments of Pharmacology Pathology, Cell Biology, Protein Chemistry, Mammalian Cell Molecular Biology, and Mammalian Genomics, Amgen, Inc, Thousand Oaks, California, USA
    Am J Pathol 157:435-48. 2000

Collaborators

Detail Information

Publications5

  1. ncbi The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
    T L Burgess
    Department of Mammalian Cell Molecular Biology, Amgen Inc, Thousand Oaks, California 91320 1789, USA
    J Cell Biol 145:527-38. 1999
    ..Together, these findings indicate that, in addition to their effects on OC precursors, OPGL and OPG have profound and direct effects on mature OCs and indicate that the OC receptor, RANK, mediates OPGL's effects...
  2. ncbi Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
    Teresa Burgess
    Department of Oncology Research, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 1799, USA
    Cancer Res 66:1721-9. 2006
    ..These results suggest that an antibody to an epitope in the beta-chain of HGF has potential as a novel therapeutic agent for treating patients with HGF-dependent tumors...
  3. ncbi Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor
    Teresa L Burgess
    Amgen Inc, Thousand Oaks, California 91320 1799, USA
    Mol Cancer Ther 9:400-9. 2010
    ..Currently, AMG 102 is in phase II clinical trials in a variety of solid tumor indications. Mol Cancer Ther; 9(2); 400-9...
  4. ncbi Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors
    J Faust
    Department of Pathology, Amgen Inc, Thousand Oaks, California 91320, USA
    J Cell Biochem 72:67-80. 1999
    ..Further characterization of these cells should identify factors involved in the growth, terminal differentiation and activation of osteoclasts...
  5. ncbi Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
    D L Lacey
    Departments of Pharmacology Pathology, Cell Biology, Protein Chemistry, Mammalian Cell Molecular Biology, and Mammalian Genomics, Amgen, Inc, Thousand Oaks, California, USA
    Am J Pathol 157:435-48. 2000
    ..Therefore, OPGL is essential, but not sufficient, for osteoclast survival and endogenous CSF-1 levels are insufficient to maintain osteoclast viability in the absence of OPGL...